Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

BACKGROUND: This trial evaluated the feasibility and efficacy of combined sorafenib and irinotecan (NEXIRI) as second- or later-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC), who had progressed after irinotecan-based chemotherapy. METHODS: In Phase I, in a 3+3 dose...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Samalin, E, Bouché, O, Thézenas, S, Francois, E, Adenis, A, Bennouna, J, Taieb, J, Desseigne, F, Seitz, J F, Conroy, T, Galais, M P, Assenat, E, Crapez, E, Poujol, S, Bibeau, F, Boissière, F, Laurent-Puig, P, Ychou, M, Mazard, T
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group 2014
Fag:
Clinical Study
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3950852/
https://ncbi.nlm.nih.gov/pubmed/24407191
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.813
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker